Paula Y.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
- Phase 3 Randomized Study of Subcutaneous Daratumumab Versus Active Monitoring in High-Risk Smoldering Multiple Myeloma Patients
- Pharmacokinetic-Guided Dosing of Emicizumab in Patients with Congenital Hemophilia A: A Non-Inferiority Study
Data & Insights
Has run more than one trial at 79 of 213 partner sites.
Specializations
Multiple Myeloma Management
The investigator specializes in treating various stages of multiple myeloma, with particular focus on newly diagnosed cases and treatment-resistant forms. Their research encompasses innovative therapeutic approaches for both transplant-eligible patients and those with relapsed/refractory disease.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- Autologous Stem Cell Transplantation
Hematologic Conditions
Their expertise extends to various blood disorders, including immune thrombocytopenia and AL amyloidosis. The investigator has particular interest in treating early-stage blood conditions, including smoldering multiple myeloma.
- Systemic AL Amyloidosis
- High-risk Smoldering Multiple Myeloma
- Immune Thrombocytopenia (ITP)
Novel Therapeutic Approaches
The investigator focuses on developing and implementing combination therapy strategies using novel agents. Their work includes evaluation of monoclonal antibodies and innovative drug combinations for hematologic malignancies.
- Antibody-based Therapies
- Multi-drug Combinations
- Targeted Treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.